In early-stage Non-small Cell Lung Cancer (NSCLC), post-treatment recovery from surgical treatment might be difficult especially for older patients. In those situations, Stereotactic Body Radiation Therapy (SBRT) might be a good option to lower mortality risk finds a new study. The findings of this study are published in the Journal of Clinical Oncology.
The study analyzed cases from the National Cancer Database (NCDB) and included 76,623 patients treated with surgery and 8,216 treated with focused radiation. The analysis showed low rates of post-treatment mortality overall - 2.1 percent of patients receiving surgery passed away within 30 days of treatment, compared with 0.7 percent of patients treated with focused radiation.
Cell Signaling Interaction Prevents Lung Cancer Progression
Lung cancers are often diagnosed in later stages, with very few treatment options available, and often patients develop a resistance to a targeted therapy.
Advertisement
‘In early-stage lung cancer patients for whom recovery from surgery is predicted to be especially challenging due to older age, focused radiation could be a better option to lower the risk of post-treatment complications.’
Tweet it Now
However, the difference in post-treatment mortality between these two treatments widened with age. Among patients older than 80 years, 3.9 percent receiving surgery passed away within this 30-day post-treatment window, compared with 0.9 percent of patients receiving focused radiation.
"When examining patients together across all age groups, there was slightly less post-treatment mortality with radiation than with surgery. But in older age groups, the differences became larger and potentially more meaningful for patients who are candidates for both therapies," says William Stokes, MD, senior resident at the CU School of Medicine Department of Radiation Oncology and the paper's first author.
![Nearly 15% of Lung Cancers are Caused by EGFR Mutation]( "Nearly 15% of Lung Cancers are Caused by EGFR Mutation")
By pairing an anti-EGFR drug with a tail , tarloxitinib brings the drug to tumors while keeping concentrations safe in surrounding tissues.
National guidelines recommend surgery as the first choice in treating early-stage lung cancer. An emerging treatment option is the use of precisely targeted radiation, sometimes referred to as Stereotactic Body Radiation Therapy (SBRT) to target tumors without surgery.
The current analysis suggests that in early-stage lung cancer patients for whom recovery from surgery is predicted to be especially challenging (perhaps due to older age or underlying illnesses), SBRT may be a good option to lower the risk of post-treatment complications.
Studies currently underway hope to evaluate the longer-term efficacy of these two treatments - it may be that despite being carrying more near-term risk, surgery remains the more effective long-term option.
"For patients with early-stage lung cancer who are otherwise healthy and good surgical candidates, lobar resection remains the standard. However, the results of this study may be important to consider when discussing the treatment options for older patients who are thought to have a high risk of surgical complications," says Chad G. Rusthoven, MD, assistant professor in Radiation Oncology at the University of Colorado Cancer Center, the paper's senior author.
In this study, for patients 71-75 years old, surgery carried an additional 1.87 percent risk of mortality over SBRT in the 30 days following treatment; for patients 76-80 years, there was an additional 2.8 percent risk associated with surgery; and for patients greater than 80 years old, surgery carried a 3.03 greater chance than SBRT of mortality in the 30 days after treatment. A similar trend was seen in measurements taken at 90 days following treatment.
The finding takes place in the context of an interesting discussion in cancer care. Traditionally, oncology discussions have emphasized patient survival at the 5-year landmark after diagnosis - even if the treatment that leads to the highest predicted long-term survival carries greater risk of near-term mortality.
However, "priorities can vary widely from patient to patient - some patients may be more concerned about the risk for near-term mortality rather than what happens after five years," Stokes says.
This study, the researchers say, may help to guide the shared decision-making between patients and providers, allowing patients who may be at greater risk of early mortality and/or patients with specific lifespan priorities to make more informed choices between surgery and SBRT to treat early-stage lung cancer.
"This analysis of patient outcomes from centers around the country showed low rates of post-treatment mortality with both surgery and radiation, which is very encouraging. Larger differences in post-treatment mortality were observed among older patients, and this information may be helpful to the discussion of treatment options with our patients," Rusthoven says.
Source: Eurekalert
Nearly 15% of Lung Cancers are Caused by EGFR Mutation
By pairing an anti-EGFR drug with a tail , tarloxitinib brings the drug to tumors while keeping concentrations safe in surrounding tissues.
Advertisement
National guidelines recommend surgery as the first choice in treating early-stage lung cancer. An emerging treatment option is the use of precisely targeted radiation, sometimes referred to as Stereotactic Body Radiation Therapy (SBRT) to target tumors without surgery.
The current analysis suggests that in early-stage lung cancer patients for whom recovery from surgery is predicted to be especially challenging (perhaps due to older age or underlying illnesses), SBRT may be a good option to lower the risk of post-treatment complications.
Studies currently underway hope to evaluate the longer-term efficacy of these two treatments - it may be that despite being carrying more near-term risk, surgery remains the more effective long-term option.
"For patients with early-stage lung cancer who are otherwise healthy and good surgical candidates, lobar resection remains the standard. However, the results of this study may be important to consider when discussing the treatment options for older patients who are thought to have a high risk of surgical complications," says Chad G. Rusthoven, MD, assistant professor in Radiation Oncology at the University of Colorado Cancer Center, the paper's senior author.
In this study, for patients 71-75 years old, surgery carried an additional 1.87 percent risk of mortality over SBRT in the 30 days following treatment; for patients 76-80 years, there was an additional 2.8 percent risk associated with surgery; and for patients greater than 80 years old, surgery carried a 3.03 greater chance than SBRT of mortality in the 30 days after treatment. A similar trend was seen in measurements taken at 90 days following treatment.
The finding takes place in the context of an interesting discussion in cancer care. Traditionally, oncology discussions have emphasized patient survival at the 5-year landmark after diagnosis - even if the treatment that leads to the highest predicted long-term survival carries greater risk of near-term mortality.
However, "priorities can vary widely from patient to patient - some patients may be more concerned about the risk for near-term mortality rather than what happens after five years," Stokes says.
This study, the researchers say, may help to guide the shared decision-making between patients and providers, allowing patients who may be at greater risk of early mortality and/or patients with specific lifespan priorities to make more informed choices between surgery and SBRT to treat early-stage lung cancer.
"This analysis of patient outcomes from centers around the country showed low rates of post-treatment mortality with both surgery and radiation, which is very encouraging. Larger differences in post-treatment mortality were observed among older patients, and this information may be helpful to the discussion of treatment options with our patients," Rusthoven says.
Source: Eurekalert
The Cause of Lung Cancer-Associated Dyspnea Identified
Lung cancer triggers pulmonary hypertension. Dyspnea is common among patients with advanced-stage lung cancer, research identified the cause.
Advertisement
 Study Analyses EGFR Mutations in Cerebrospinal Fluid of Lung Cancer PatientsStudy analyses epidermal growth factor receptor (EGFR) mutations in cerebrospinal fluid of patients with lung cancer. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
The presence of painless swelling in the lymph nodes could potentially indicate lymphatic cancer, say experts.
Women tested at high risk for breast cancer using non-clinical genetic tests overlooking family history may decide to undergo unnecessary breast surgery.
